Lilly completes acquisition of AtaiBeckley to advance therapies for treatment-resistant depression and other mental health conditions
New Phase 3b data on Lilly's Taltz and Zepbound used together showed improved and durable efficacy at one year in adults with psoriatic disease and obesity
Lilly to acquire Merida Biosciences to advance treatments for serious autoimmune and allergic diseases
Zepbound linked to lower healthcare costs in adults over age 55 with obesity according to a real-world study
Most AI Drug Discovery Reads the Genetic Code. The Next Wave Is Learning to Read What the Code Actually Does.
Lilly reports second-quarter 2026 financial results, raises full-year guidance, and highlights continued growth and pipeline progress
Lilly's olomorasib receives U.S. FDA's Breakthrough Therapy designation for the treatment of previously treated KRAS G12C-mutant advanced pancreatic cancer
Lilly's triple agonist, retatrutide, successful in two additional Phase 3 obesity trials, delivering significant improvements in weight and A1C
Lilly to acquire AtaiBeckley to advance therapies for treatment-resistant depression and other mental health conditions
Lilly to present Alzheimer's disease diagnostic and therapeutic research at AAIC 2026, including new data on P-tau217 blood tests and amyloid-targeting treatment
Steadright Critical Minerals Inc. to Acquire up to 75% Interest in the Péribonka Ree-Niobium Carbonatite Project, Saguenay-Lac-St-Jean Region, Québec
Prismo Metals Announces Listing of Blade Resources on the CSE Prismo Metals Owns 6,755,000 Shares of Blade Resources
Goldgroup Highlights Its Two Producing Mines and Significant Growth Potential Across the Don David Gold Complex in Mexico
